Ceryvyn Therapeutics Ltd
OPT
Classificação em ações
#31793
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Preço da ação
$0.00846342
Última sincronização: 2026-07-27
Valor de mercado
$11.27M
Variação (1 dia)
0.00%
Variação (1 ano)
-99.75%
País
AU
Negociar Ceryvyn Therapeutics Ltd (OPT)
Categoria
Healthcare
Histórico de preços das ações de Ceryvyn Therapeutics Ltd (OPT)
Preço de fecho mais alto: $3.41 em 2025-04-01
Preço de fecho mais baixo: $13.17 em 2020-10-01
Preço de fecho mais baixo: $13.17 em 2020-10-01
Histórico de preços das ações da Ceryvyn Therapeutics Ltd de 2020 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2025 | -4.06% |
| 2024 | 37.44% |
| 2023 | -49.05% |
| 2022 | -27.97% |
| 2021 | -41.46% |
| 2020 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
